Excess mortality in England post COVID-19 pandemic: implications for secondary prevention
Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism
Research shows that the procoagulant state of PBMC could aid in the early detection of PE in COVID-19 ICU patients. When combined with the end-tidal to ETCO2 – PaCO2 gradient, these tests could improve the early detection of PE in the ICU.
The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research
In the last three years, extensive research has demonstrated the safety and efficacy of COVID-19 vaccines. These vaccines have played a critical role in reducing mortality and hospitalization rates.
Variant-adapted COVID-19 booster vaccines
Current vaccines should be tailored to combat future SARS-CoV-2 variants.
WHO/Europe, EC and ECDC urge eligible groups to get vaccinated or boosted to save lives this autumn and winter
Last year’s autumn and winter seasons were unpredictable. Last winter, the cumulative impacts of influenza, COVID-19, and respiratory syncytial virus or RSV hit the very young and the very old the hardest.
|
9th Influenza Conference 2023
The Ninth ESWI Influenza Conference: Highlights
ESWI 2023: 10 key take home messages
Scientific Papers
News
Article
Effectiveness of community-based oral antiviral treatments against severe COVID-19 outcomes in people 70 years and over in Victoria, Australia, 2022: an observational study
Oral Antiviral (OAV) COVID-19 treatments are widely used, but evidence for their effectiveness against the Omicron variant in higher risk, vaccinated individuals is limited.
Scientific Papers
Article
News
Factors associated with delayed diagnosis of symptomatic adult COVID-19 cases presenting to primary care: a population-wide study during transition from Delta to Omicron BA.1 in Singapore
During pandemics, avoiding time delay in diagnosing infection is crucial.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part
Benefits of ensitrelvir in Covid-19 and long Covid highlighted in two studies
The benefits of ensitrelvir use in patients with symptoms of long Covid and as a second-line treatment option for those hospitalised with Covid-19.
Joint EMA-ECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA
As autumn season approaches the EMA and ECDC held a press briefing to provide latest information on respiratory diseases as well as vaccines and treatments available
